NEO Neogenomics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NEO

Price (delayed)

$16.095

Market cap

$2.07B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.39

Enterprise value

$2.37B

?
Relative Growth: Rel. Growth: 74
Relative Strength: Rel. Strength: 96
Relative Valuation: Rel. Valuation: 18
Relative Profitability: Rel. Profitability: 38

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, ...

Highlights
The company's EPS has surged by 52% YoY and by 49% QoQ
The net income has soared by 50% YoY and by 48% from the previous quarter
The quick ratio has contracted by 18% from the previous quarter and by 4.1% YoY
NEO's debt is up by 10% QoQ and by 9% YoY
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.neogenomics.com
Peers: RDNT DGX LH

Key stats

What are the main financial stats of NEO

NEO stock price

How has the Neogenomics stock price performed over time
Intraday
5.26%
1 week
22.49%
1 month
6.17%
1 year
211.92%
YTD
36.86%
QTD
10.32%

Financial performance

How have Neogenomics's revenue and profit performed over time
Revenue
$766.3M
Gross profit
$336.53M
Operating income
-$68.44M
Net income
-$51.88M
Gross margin
43.9%
Net margin
-6.8%
NEO's net margin has soared by 55% YoY and by 49% QoQ
The net income has soared by 50% YoY and by 48% from the previous quarter
Neogenomics's operating margin has increased by 47% YoY and by 37% from the previous quarter
The company's operating income rose by 41% YoY and by 36% QoQ

Price vs fundamentals

How does NEO's price correlate with its fundamentals

Growth

What is Neogenomics's growth rate over time

Valuation

What is Neogenomics stock price valuation
NEO P/E details
P/E
N/A
P/B
2.67
P/S
2.72
EV/EBIT
N/A
EV/EBITDA
116
EV/Sales
3.09
The company's EPS has surged by 52% YoY and by 49% QoQ
The price to book (P/B) is 58% more than the last 4 quarters average of 1.6 and 27% more than the 5-year quarterly average of 2.0
The equity is down by 8% year-on-year and by 5% since the previous quarter
The price to sales (P/S) is 44% higher than the last 4 quarters average of 1.8 but 22% lower than the 5-year quarterly average of 3.3
The revenue rose by 11% YoY and by 2.7% QoQ

Efficiency

How efficient is Neogenomics business performance
The company's return on sales has surged by 53% YoY and by 49% QoQ
NEO's ROIC is up by 48% since the previous quarter and by 48% year-on-year
The return on assets rose by 47% since the previous quarter and by 42% year-on-year
The return on equity has increased by 47% since the previous quarter and by 46% year-on-year

Dividends

What is NEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NEO.

Financial health

How did Neogenomics financials performed over time
The total assets is 139% greater than the total liabilities
NEO's current ratio is down by 19% from the previous quarter and by 8% YoY
The quick ratio has contracted by 18% from the previous quarter and by 4.1% YoY
NEO's debt is 43% lower than its equity
The debt to equity rose by 19% year-on-year and by 16% since the previous quarter
NEO's debt is up by 10% QoQ and by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.